SpyGlass Pharma, Inc. — Investor Relations & Filings

SpyGlass Pharma, Inc. is an ophthalmic biotechnology company focused on developing a proprietary drug delivery platform for the treatment of chronic eye diseases, specifically glaucoma and cataracts. The company’s core technology is a non-bioerodible drug delivery system integrated with an intraocular lens (IOL), designed to provide sustained medical therapy for up to three years. By delivering medication directly to targeted ocular tissues during standard cataract surgery, the platform aims to address patient compliance issues and the treatment gap associated with daily topical therapies. Clinical data for its lead program, which utilizes bimatoprost, demonstrates significant reduction in intraocular pressure. SpyGlass Pharma focuses on providing long-term, automated management of ophthalmic conditions to improve patient outcomes and simplify treatment regimens for those with mild-to-moderate glaucoma.